Assessing Hibiscus rosa-sinensis Linn as an Excipient in Sustained-Release Tablets - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Assessing Hibiscus rosa-sinensis Linn as an Excipient in Sustained-Release Tablets
Natural gums and mucilage are biocompatible, cheap, readily available, and represent a potential source of excipients. The authors examine the functionality of mucilage extracted from the leaves of Hibiscus rosa-sinensis Linn as an excipient in a sustained-release tablet formulation.


Pharmaceutical Technology
Volume 32, Issue 1


Figure 3
Drug and mucilage mixture. Mucilage matrices contained diclofenac sodium of the optimized batch (HL6) in proportions of 1:2 of the drug to mucilage, respectively. Figure 3 shows the percentage increase in weight resulting from water uptake in distilled water at various agitation speeds. No significant differences in weight gain (i.e., water uptake) between matrices containing the drug at the two different agitation speeds were observed. The only significant differences in weight gain were shown for matrices containing different proportions of mucilage. Matrices containing a lower proportion of mucilage (1:1) showed a lower degree of weight gain with time. This result is expected because the lower proportion of mucilage would decrease the ability of the matrix to absorb water. The dynamic balance between weight gain resulting from water uptake and weight loss resulting from mucilage erosion and drug dissolution was further illustrated by the profiles for mucilage matrices containing diclofenac sodium at both agitation speeds. Figure 4 shows the percentage of erosion into distilled water at two agitation speeds. An initial rapid uptake of water by the dry matrices occurred during the first 2 h, followed by a leveling off of the wet weights because of the increasing rate of erosional release at 100 rpm. This condition persists until the rate of erosion exceeded the rate of water uptake, with a resultant decrease in weight with time.


Figure 4
Table VI shows the results of the radial and axial study. The data show that the increase in diameter and thickness was proportionate with time. More swelling, however, occurred in the axial direction compared with the radial direction.


Table VI: Radial and axial swelling study of optimized batch (HL6).
To study the effect of storage on in vitro drug release, a stability study of the best formulation (HL6) was carried out at 40 C and 75% relative humidity in a humidity oven. Samples were withdrawn after a three-month interval and in vitro drug release was carried out. No change in the in vitro drug release pattern occurred. The value of the similarity factor was 82.14, which indicated a good similarity of dissolution profile before and after stability studies. The calculated t-value (0.997) was smaller than the tabulated value (2.577), which indicated an insignificant difference in the dissolution profile before and after the stability study.

Conclusion

The authors conclude that a novel hydrophilic excipient, such as mucilage extracted from Hibiscus rosa-sinensis Linn, can be used for the development of sustained-release tablets. The dried mucilage powder shows superior swelling capacity and is pH independent. The mucilage can be further explored as a disintegrating agent, gelling agent and modified-release dosage form.

Girish K. Jani, PhD,* is a principal at K.B. Raval College of Pharmacy at Sheratha Post Kasturinagar, Gandhinagar, Gujarat, India 382423, tel.+ 91 793 252 9996, fax +91 792 928 9767,
Dhiren P. Shah is an assistant professor at C.K. Pithawala Institute of Pharmaceutical Science and Research, Surat, India.

* To whom correspondence should be addressed.

Submitted: Apr. 6, 2007. Accepted May 24, 2007.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
9%
All of the above.
45%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here